Medical device company Avinger (NASDAQ: AVGR) has announced that it has received clearance from the US Food and Drug Administration (FDA) for its Ocelaris next-generation image-guided total occlusion crossing system.
The catheter-based system will be branded as TIGEREYE and provides real-time imaging from inside the vessel during a CTO-crossing procedure.
“We are excited to receive U.S. pre-marketing clearance for TIGEREYE, which we believe will be a significant growth driver for our CTO-crossing business,” said Jeff Soinski, Avinger’s President and CEO.
Sponsored content
Interested in investing after today’s move?
XTB gives investors access to thousands of UK and international stocks,
including fractional shares from just £1.
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
The company believes it is a significant advancement for patients with chronic total occlusions and provides Avinger with a market growth opportunity as chronic total occlusions present a technical challenge to physicians treating peripheral artery disease.
AVGR Share Price…
Avinger $AVGR/Source: TradingView
The news has sent Avinger’s share price racing higher. It is currently trading at $0.52 per share premarket, up 25%.
Sam is a trader and lead stock market writer at AskTraders. After starting his career in the forex market, Sam now focuses on stocks, specifically consumer staples.
